Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New liposomal drug shows promise in early solid tumor trial

NCT ID NCT03207672

First seen Feb 25, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This early-phase study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study includes people with several cancer types, including breast cancer, and aims to see if the drug can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Eisai Trial Site 1

    Chuo-ku, Tokyo, Japan

  • Eisai Trial Site 10

    Hidaka, Saitama, Japan

  • Eisai Trial Site 11

    Kyoto, Japan

  • Eisai Trial Site 12

    Fukuoka, Japan

  • Eisai Trial Site 2

    Osaka, Japan

  • Eisai Trial Site 3

    Kashiwa, Chiba, Japan

  • Eisai Trial Site 4

    Koto-ku, Tokyo, Japan

  • Eisai Trial Site 5

    Sapporo, Hokkaido, Japan

  • Eisai Trial Site 6

    Yokohama, Kanagawa, Japan

  • Eisai Trial Site 7

    Shinjuku-ku, Tokyo, Japan

  • Eisai Trial Site 8

    Nishinomiya, Hyōgo, Japan

  • Eisai Trial Site 9

    Bunkyo-ku, Tokyo, Japan

Conditions

Explore the condition pages connected to this study.